Skip to main content
United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
312.63
+4.63 (1.50%)
May 9, 2025, 9:35 AM - Market open

United Therapeutics Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Tyvaso
1.71B 1.62B 1.56B 1.45B 1.37B 1.23B 1.13B 1.06B
Tyvaso Growth
25.33% 31.34% 38.18% 36.87% 45.60% 41.32% 41.17% 50.25%
Remodulin
548.30M 538.10M 518.70M 521.50M 501.40M 494.80M 502.20M 485.10M
Remodulin Growth
9.35% 8.75% 3.29% 7.50% 2.35% -1.08% 1.25% -4.39%
Orenitram
448.80M 434.30M 410.60M 389.40M 377.40M 359.40M 351.10M 346.60M
Orenitram Growth
18.92% 20.84% 16.95% 12.35% 14.19% 10.55% 9.17% 8.55%
Unituxin
238.50M 238.70M 225.40M 215.60M 208.20M 198.90M 181.40M 176.20M
Unituxin Growth
14.55% 20.01% 24.26% 22.36% 18.03% 8.75% -7.54% -14.22%
Adcirca
23.40M 23.80M 25.90M 26.20M 28.00M 28.90M 32.50M 35.90M
Adcirca Growth
-16.43% -17.65% -20.31% -27.02% -27.84% -30.02% -16.67% -16.32%
Other
16.00M 17.20M 15.60M - 12.00M 8.30M 8.20M -
Other Growth
33.33% 107.23% 90.24% - 90.48% -39.86% - -

Revenue by Geography
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
2.85B 2.74B 2.62B 2.49B 2.37B 2.20B 2.08B 2.00B
United States Growth
19.96% 24.41% 25.96% 24.63% 26.68% 21.39% 19.78% 21.06%
International
146.30M 137.70M 136.30M 129.50M 124.30M 125.30M 124.30M 115.30M
International Growth
17.70% 9.90% 9.65% 12.32% 15.84% 2.54% 0.65% -17.82%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.